Collaboration

Addressing our chosen disease areas can only be achieved in collaboration with partners – from initial development through to the commercialization and delivery to patients. We therefore work with several leading institutions and organizations around the world to ensure that our treatments and clinical studies truly address the needs of patients and physicians.

Academic Initiatives
Evive ProgramAcademic Collaborator
F-652 for AH
  • Vijay Shah, MD – Chief of Medicine, Mayo Clinic, Professor of Medicine, Mayo Clinic Alix School of Medicine, Minnesota
F-652 for GvHD
  • Alan Hanash, MD, PhD – Assistant Member of Memorial Sloan Kettering and an Attending Physician on the Adult Bone Marrow Transplant Service in the Department of Medicine
  • Marcel van den Brink, MD, PhD – Lab Head at Memorial Sloan Kettering cancer Center
  • Doris Ponce, MD – Hematology Oncologist, Allogeneic Hematopoietic Stem Cell Transplantation; Graft-Versus-Host Disease, Memorial Sloan Kettering Cancer Center.
  • Amin M. Alousi, MD – Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
F-652 for other inflammatory disorders
  • Jay Kolls, MD – Professor of Medicine and Pediatrics, Director of the Center for Translational Research in Infection and Inflammation at the Tulane University School of Medicine
  • Misty Good, MD, MS – Assistant Professor of Pediatrics – Division of Newborn Medicine, Washington University School of Medicine, St. Louis.

In collaboration with:

Development Partnerships

Evive leverages key Contract Research Organizations (CROs) for the management of our global and China clinical trials. We partner with established CROs such as Covance and Everest Clinical Research to ensure patient safety, data integrity, and that Good Clinical Practices are in place and enforced. Working with CROs allows Evive Biotech to leverage internal Medical Affairs and Clinical Operations at scale in our global trials

In collaboration with:

Commercial Collaborations

Evive Biotech is exploring strategic partners for the development and commercialization of many of our current programs as well as partners for new assets that can leverage Evive Biotech’s technology.

Specific partnering initiatives include:

Evive Program Indication Partnership
F-627 for CIN F-627 is a novel dimeric recombinant human granulocyte colony stimulating factor fusion protein for the treatment of Chemotherapy Induced Neutropenia Evive Biotech is seeking partners for commercialization of F-627 in the US, markets throughout Europe and ROW
F-652 for AH F-652 is a novel dimeric IL-22 fusion protein that has completed Phase IIa trials for moderate to severe Alcoholic Hepatitis, for which current standard of care is steroids Evive Biotech is developing AH in-house and open for global co-development partnerships of other indications related to AH
F-652 for GvHD F-652 is a novel dimeric IL-22 fusion protein that has completed Phase IIa trial for Acute Graft vs Host Disease Evive Biotech is open for global co-development partnerships of F-652 for GvHD and potentially for other inflammatory disorders
ITab™ for multiple forms of cancer ITab™ is a multi-specific antibody technology platform with early clinical stage development programs in solid and liquid tumors Evive Biotech is seeking partners to co-develop or license current assets for current or future indications or collaborate on development of new assets to out license